AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 463953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation Method (OM)
Number of subjects: 0
Study 463953 — intervention group
Group type: COMPARATOR
Intervention: Symptothermal Method (STM)
Number of subjects: 0
Study 31056465 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute postpartum rounding video based on 4C-ID principles
Number of subjects: 78
Study 31056465 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 78
Study 28429365 — intervention group
Group type: EXPERIMENTAL
Intervention: Screwed implant-abutment connection (Group 1)
Number of subjects: 20
Study 28429365 — intervention group
Group type: COMPARATOR
Intervention: Cemented implant-abutment connection (Group 2)
Number of subjects: 20
Study 28429365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters (PPD > 3 mm and m SBI > 0) in Group 1
Number of subjects: 20
Study 26027630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg Q2W at week 12 if LDL-C ≥70 mg/dL)
Number of subjects: 316
Study 26027630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Q2W)
Number of subjects: 316
Study 26027630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 316
Study 26027630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 26027630 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab and Placebo
Number of subjects: 316
Study 23529851 — intervention group
Group type: EXPERIMENTAL
Intervention: Group HDO (haloperidol 2 mg, dexamethasone 8 mg, ondansetron)
Number of subjects: 90
Study 23529851 — intervention group
Group type: COMPARATOR
Intervention: Group O (ondansetron 8 mg)
Number of subjects: 90
Study 20572860 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 250) received multiple measures for caries control.
Number of subjects: 497
Study 20572860 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 247) received standard dental care.
Number of subjects: 497
Study 20572860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received standard dental care during the post-trial period (2005-2008).
Number of subjects: 497
Study 20572860 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 250)
Number of subjects: 497
Study 20572860 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 247)
Number of subjects: 497
Study 18795629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg, once daily) after ESWL
Number of subjects: 80
Study 18795629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tamsulosin)
Number of subjects: 80
Study 16901180 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-day famciclovir
Number of subjects: 0
Study 16901180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12929897 — intervention group
Group type: EXPERIMENTAL
Intervention: CATCH program (FI schools)
Number of subjects: 96
Study 12929897 — intervention group
Group type: COMPARATOR
Intervention: Former control schools (FC)
Number of subjects: 96
Study 12929897 — intervention group
Group type: COMPARATOR
Intervention: Unexposed control schools (UC)
Number of subjects: 96
Study 10779188 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (3 x 10(‐6) mol. dissolved in 70% ethanol)
Number of subjects: 51
Study 10779188 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin vehicle (70% ethanol)
Number of subjects: 51
Study 8630960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile mouthwash, administered thrice daily for 14 days.
Number of subjects: 164
Study 8630960 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash, administered thrice daily for 14 days.
Number of subjects: 164
Study 10149894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hercules injections
Number of subjects: 200
Study 10149894 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual injections
Number of subjects: 200
Study 6086181 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 5
Study 6086181 — intervention group
Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 5
Study 31436395 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin (INO)
Number of subjects: 0
Study 31436395 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC; intensive chemotherapy)
Number of subjects: 0
Study 30304715 — intervention group
Group type: EXPERIMENTAL
Intervention: High miR‐125b level group (n = 77)
Number of subjects: 154
Study 30304715 — intervention group
Group type: COMPARATOR
Intervention: Low miR‐125b level group (n = 77)
Number of subjects: 154
Study 27553751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous mepolizumab treatment
Number of subjects: 558
Study 25259640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic health nurse intervention
Number of subjects: 0
Study 25259640 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23082124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance water filter and jerry cans for safe storage
Number of subjects: 120
Study 20929607 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH replacement products
Number of subjects: 0
Study 20929607 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma kallikrein inhibitor
Number of subjects: 0
Study 20929607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin B₂‐receptor antagonist
Number of subjects: 0
Study 18064330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (n = 16)
Number of subjects: 31
Study 18064330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 31
Study 18064330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 31
Study 18064330 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin
Number of subjects: 31
Study 18232183 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg three times daily for 12 weeks
Number of subjects: 129
Study 14763916 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 3 weeks (2.55 MJ)
Number of subjects: 12
Study 14763916 — intervention group
Group type: EXPERIMENTAL
Intervention: Starvation for 6 days
Number of subjects: 12
Study 10437189 — intervention group
Group type: EXPERIMENTAL
Intervention: Herba Artemisiae Scopariae, Fructus Gardeniae, Radix Scutellariae, Radix et Rhizoma Rhei Preparata
Number of subjects: 30
Study 10437189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8473583 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored videotape presented by African-American women
Number of subjects: 106
Study 8473583 — intervention group
Group type: COMPARATOR
Intervention: Standard public health service tape on AIDS prevention
Number of subjects: 106
Study 8473583 — intervention group
Group type: COMPARATOR
Intervention: Ethnically matched public health service tape
Number of subjects: 106
Study 3700932 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (10 to 20 mg daily)
Number of subjects: 24
Study 3700932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30801507 — intervention group
Group type: EXPERIMENTAL
Intervention: Microblepharon exfoliation
Number of subjects: 30
Study 30801507 — intervention group
Group type: COMPARATOR
Intervention: LidHygenix (hypoallergenic foam cleanser)
Number of subjects: 30
Study 28017406 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib with lenalidomide and dexamethasone (VRd)
Number of subjects: 525
Study 28017406 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 525
Study 25393894 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-60H IOL
Number of subjects: 65
Study 25393894 — intervention group
Group type: COMPARATOR
Intervention: Micro AY IOL
Number of subjects: 65
Study 25164259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based dietary intervention (individualized calorie goals, weight maintenance advice, Dietary Approaches to Stop Hypertension dietary pattern, weekly group meetings)
Number of subjects: 114
Study 25164259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based dietary intervention
Number of subjects: 114
Study 23866514 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba (120 mg daily dose)
Number of subjects: 56
Study 23866514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (4.5 mg daily dose)
Number of subjects: 56
Study 18785988 — intervention group
Group type: EXPERIMENTAL
Intervention: LAB4 multistrain probiotic preparation (2.5 × 10(10) cfu/capsule)
Number of subjects: 52
Study 18785988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17468062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg
Number of subjects: 225
Study 17468062 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate (ALN) 70 mg
Number of subjects: 225
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children
Number of subjects: 150
Study 15131770 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic children (control)
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic females
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic males
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with poor glycemic control (HbA(1C) > 9.0%)
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with raised total cholesterol (TC)
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with raised triglycerides (TG)
Number of subjects: 150
Study 15131770 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic children with family history of cardiovascular disease (CVD)
Number of subjects: 150
Study 11395209 — intervention group
Group type: EXPERIMENTAL
Intervention: Granzyme B levels in peripheral blood mononuclear cells stimulated with live influenza virus
Number of subjects: 100
Study 11395209 — intervention group
Group type: COMPARATOR
Intervention: Cytokine levels in peripheral blood mononuclear cells stimulated with live influenza virus
Number of subjects: 100
Study 9741525 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous ultrafiltration (UF) immediately after CPB (Group A)
Number of subjects: 23
Study 9741525 — intervention group
Group type: EXPERIMENTAL
Intervention: Veno-venous ultrafiltration (UF) 10 min after CPB (Group B)
Number of subjects: 23
Study 8116042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment with 10 courses of photochemotherapy (PCT)
Number of subjects: 15
Study 8116042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct treatment with 20 courses of photochemotherapy (PCT)
Number of subjects: 15
Study 8116042 — intervention group
Group type: COMPARATOR
Intervention: Control group with no additional treatment
Number of subjects: 15
Study 8116042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCT schedules (10 and 20 courses)
Number of subjects: 15
Study 3136642 — intervention group
Group type: EXPERIMENTAL
Intervention: High lysine (206 mg.kg‐1.d‐1)
Number of subjects: 23
Study 3136642 — intervention group
Group type: COMPARATOR
Intervention: Low lysine (158 mg.kg‐1.d‐1)
Number of subjects: 23
Study 3136642 — intervention group
Group type: EXPERIMENTAL
Intervention: High threonine (147 mg.kg‐1.d‐1)
Number of subjects: 23
Study 3136642 — intervention group
Group type: COMPARATOR
Intervention: Low threonine (113 mg.kg‐1.d‐1)
Number of subjects: 23
Study 3136642 — intervention group
Group type: EXPERIMENTAL
Intervention: High histidine (124 mg.kg‐1.d‐1)
Number of subjects: 23
Study 3136642 — intervention group
Group type: COMPARATOR
Intervention: Low histidine (85 mg.kg‐1.d‐1)
Number of subjects: 23
Study 31361922 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg annually
Number of subjects: 43
Study 31361922 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) switching
Number of subjects: 43
Study 28583098 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in Relational Capacity by one standard deviation
Number of subjects: 113
Study 28583098 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity Integration
Number of subjects: 113
Study 28583098 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control
Number of subjects: 113
Study 25644342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based bread
Number of subjects: 30
Study 25644342 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 30
Study 23866736 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ Winthrop®)
Number of subjects: 1300
Study 23866736 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL, Coartem®)
Number of subjects: 1300
Study 23866736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASAQ and AL
Number of subjects: 1300
Study 21788827 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy on tissue expanders (group 2)
Number of subjects: 257
Study 21788827 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy on permanent implants (group 1)
Number of subjects: 257
Study 21788827 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated control group
Number of subjects: 257
Study 19830868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcon CZ70BD PMMA suspensory IOL (Group I)
Number of subjects: 23
Study 19830868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Akreos Adapt four-haptic hydrophilic acrylic foldable IOL (Group II)
Number of subjects: 23
Study 18038919 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg at weeks 0 and 2, open-label infliximab 5mg/kg at weeks 6 and 14
Number of subjects: 19
Study 18038919 — intervention group
Group type: COMPARATOR
Intervention: Placebo at weeks 0 and 2, open-label infliximab 5mg/kg at weeks 6 and 14
Number of subjects: 19
Study 15356432 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium
Number of subjects: 0
Study 14627176 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan/HCTZ (50 mg/12.5 mg)
Number of subjects: 0
Study 14627176 — intervention group
Group type: COMPARATOR
Intervention: losartan (50 mg)
Number of subjects: 0
Study 11128853 — intervention group
Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in lower leg muscles increased from 24.6 +/- 9.5% to 43.1 +/- 4.7%; P < 0.05
Number of subjects: 12
Study 11128853 — intervention group
Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in heart increased from 2.3 +/- 0.4% to 2.8 +/- 0.6%; P < 0.05
Number of subjects: 12
Study 11128853 — intervention group
Group type: COMPARATOR
Intervention: Resting for 35 min after FDG injection; FDG uptake in abdominal region reduced from 37.3 +/- 7.2% to 19.7 +/- 4.9%; P < 0.05
Number of subjects: 12
Study 11128853 — intervention group
Group type: EXPERIMENTAL
Intervention: Running for 35 min with FDG injection after 15 min; FDG uptake in brain remained stable at 11.9 +/- 2.8% at rest and 10.3 +/- 2.5% after exercise; P not specified
Number of subjects: 12
Study 9175961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-extradural technique with 2.25 ml of 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study 1398497 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus sclerotherapy
Number of subjects: 131
Study 1398497 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 131
Study 3083995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg prednisolone daily
Number of subjects: 10
Study 3083995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg prednisolone daily
Number of subjects: 10
Study 3083995 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg prednisolone daily
Number of subjects: 10
Study 31678411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional prehabilitation
Number of subjects: 0
Study 29898838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ng IGF1
Number of subjects: 47
Study 29898838 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ng IGF1
Number of subjects: 47
Study 29898838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 26924243 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 125 mg
Number of subjects: 10
Study 26924243 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 25 mg
Number of subjects: 10
Study 26924243 — intervention group
Group type: EXPERIMENTAL
Intervention: Camicinal 50 mg
Number of subjects: 10
Study 26924243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (mean dose 5.5 mg/day)
Number of subjects: 59
Study 23801256 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 1.12 mg/day)
Number of subjects: 59
Study 23801256 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 59
Study 23801256 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 59
Study 22764184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) measured using a sensitive assay (VITROS Trop I ES, Ortho Clinical Diagnostics)
Number of subjects: 808
Study 22764184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 808
Study 20082200 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative orbital floor triamcinolone acetonide (1 ml = 40 mg)
Number of subjects: 40
Study 20082200 — intervention group
Group type: COMPARATOR
Intervention: 4‐week postoperative oral prednisolone
Number of subjects: 40
Study 19013239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% DHEA cream
Number of subjects: 60
Study 19013239 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% DHEA cream
Number of subjects: 60
Study 19013239 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% DHEA cream
Number of subjects: 60
Study 19013239 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DHEA
Number of subjects: 60
Study 19013239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% DHEA cream)
Number of subjects: 60
Study 15907404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg/day, n = 48)
Number of subjects: 96
Study 15907404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 96
Study 12789465 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 399
Study 12789465 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 399
Study 10721943 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy with axillary dissection
Number of subjects: 1053
Study 10721943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumours of size 1-9 mm
Number of subjects: 1053
Study 10721943 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary adjuvant therapy
Number of subjects: 1053
Study 10721943 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 1053
Study 8520606 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD insertion by physicians
Number of subjects: 1711
Study 8520606 — intervention group
Group type: COMPARATOR
Intervention: IUD insertion by nurses
Number of subjects: 1711
Study 8520606 — intervention group
Group type: COMPARATOR
Intervention: IUD insertion by physicians (nulliparous)
Number of subjects: 1711
Study 8520606 — intervention group
Group type: COMPARATOR
Intervention: IUD insertion by nurses (nulliparous)
Number of subjects: 1711
Study 8520606 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complication rate
Number of subjects: 1711
Study 2019190 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lateral rotational therapy (CLRT)
Number of subjects: 0
Study 2019190 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed treatment (turned every 2 hours)
Number of subjects: 0
Study 2019190 — intervention group
Group type: COMPARATOR
Intervention: Conventional bed treatment
Number of subjects: 0
Study 6290435 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg oral
Number of subjects: 6
Study 31042143 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist telephone-delivered CBT (TCBT)
Number of subjects: 558
Study 31042143 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based CBT (WCBT)
Number of subjects: 558
Study 31042143 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 558
Study 28874171 — intervention group
Group type: EXPERIMENTAL
Intervention: Galium‐Heel® (low‐dose multicomponent medicine) administered twice a day for six non‐consecutive months
Number of subjects: 80
Study 28874171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 80
Study 28874171 — intervention group
Group type: EXPERIMENTAL
Intervention: Galium‐Heel® (low‐dose multicomponent medicine)
Number of subjects: 80
Study 25439772 — intervention group
Group type: EXPERIMENTAL
Intervention: Epic bioprosthesis (n=99)
Number of subjects: 300
Study 25439772 — intervention group
Group type: EXPERIMENTAL
Intervention: Magna bioprosthesis (n=100)
Number of subjects: 300
Study 25439772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitroflow bioprosthesis (n=101)
Number of subjects: 300
Study 25439772 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300
Study 23743472 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative gum chewing every 2 hours for 15 minutes
Number of subjects: 179
Study 23743472 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care without gum chewing
Number of subjects: 179
Study 21371699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 372
Study 21371699 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 372
Study 21371699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 372
Study 21371699 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 372